Mon, Dec 23, 2024
[Archive]
Volume 15, Issue 1 (1-2025)
Iran J Ped Hematol Oncol 2025, 15(1): 338-346 |
Back to browse issues page
Ethics code: IR.SUMS.REC.1399.450
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Farokhian F, Cohan N, Ramzi M, Abedi E, Fakhraei F, Parand S, et al . The Gene Expression Levels of ETS2, ADAM28, and GPRC5D Genes in Acute Lymphoblastic Leukemia Patients. Iran J Ped Hematol Oncol 2025; 15 (1) :338-346
URL: http://ijpho.ssu.ac.ir/article-1-885-en.html
URL: http://ijpho.ssu.ac.ir/article-1-885-en.html
Farnoush Farokhian 
, Nader Cohan , Mani Ramzi , Elham Abedi , Farzaneh Fakhraei , Shirin Parand , Reyhane Khademi , Mohamad Moghadam *
, Nader Cohan , Mani Ramzi , Elham Abedi , Farzaneh Fakhraei , Shirin Parand , Reyhane Khademi , Mohamad Moghadam *
Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran & Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Abstract: (38 Views)
Background: Genetic biomarkers significantly influence the pathological differentiation and proliferation of lymphoid precursor cells, contributing to the development of Acute Lymphoblastic Leukemia (ALL) in children. This case-control study aimed to assess the expression levels of three potential biomarkers: ETS2, ADAM28, and GPRC5D, in patients with ALL.
Materials and Methods: In this cross-sectional study, a group of ALL patients (n=65) referred to the hematology-oncology departments of Nemazee Hospital and Amir Hospital in Shiraz, Iran, from May 2018 to May 2021 were selected as the patient group. A control group (n=65) of age- and gender-matched volunteers was also selected.
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to study the expression profiles of these genes in patients and compare the results to those of a control group. The study included 65 patients with ALL and 65 healthy participants. The Pfaffl method of relative quantification, which compares the threshold cycle of a constitutive gene (TBP) with the test gene of each sample in duplicate, was used to determine the relative levels of ETS2, ADAM28, and GPRC5D gene expression. SPSS software version 16 was used for statistical analysis. Nonparametric tests were used to analyze non-normally distributed data, and the Mann-Whitney test was used to compare the medians and ranges and a p-value of 0.05 was considered significant.
Results: The patient group showed significantly greater expression of the ETS2 and ADAM28 genes compared to the control group. (P <0.0001; fold changes of 2.80 and 2.14, respectively), while GPRC5D expression remained unchanged (P >0.05).
Conclusion: These genetic biomarkers in patients with ALL may play an oncogenic role in the pathogenesis of the disease and could serve as potential novel biomarkers for ALL.
Materials and Methods: In this cross-sectional study, a group of ALL patients (n=65) referred to the hematology-oncology departments of Nemazee Hospital and Amir Hospital in Shiraz, Iran, from May 2018 to May 2021 were selected as the patient group. A control group (n=65) of age- and gender-matched volunteers was also selected.
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to study the expression profiles of these genes in patients and compare the results to those of a control group. The study included 65 patients with ALL and 65 healthy participants. The Pfaffl method of relative quantification, which compares the threshold cycle of a constitutive gene (TBP) with the test gene of each sample in duplicate, was used to determine the relative levels of ETS2, ADAM28, and GPRC5D gene expression. SPSS software version 16 was used for statistical analysis. Nonparametric tests were used to analyze non-normally distributed data, and the Mann-Whitney test was used to compare the medians and ranges and a p-value of 0.05 was considered significant.
Results: The patient group showed significantly greater expression of the ETS2 and ADAM28 genes compared to the control group. (P <0.0001; fold changes of 2.80 and 2.14, respectively), while GPRC5D expression remained unchanged (P >0.05).
Conclusion: These genetic biomarkers in patients with ALL may play an oncogenic role in the pathogenesis of the disease and could serve as potential novel biomarkers for ALL.
Type of Study: Research |
Subject:
Oncology
Received: 2024/08/6 | Accepted: 2025/01/23 | Published: 2025/01/23
Received: 2024/08/6 | Accepted: 2025/01/23 | Published: 2025/01/23
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
